According to the National Family Health Survey-5 (2019–21), 24% of Indian women and 23% of Indian men are either overweight ...

BMO Capital Markets downgraded Verve Therapeutics to Market perform, saying Eli Lilly’s agreement to buy the gene-editing specialist leaves limited room for the stock to rise before the transaction is ...

Reuters, the news and media division of Thomson Reuters, is the world’s largest multimedia news provider, reaching billions ...

In the race to make the most tolerable obesity drug, there seems to be no clear winner—at least not according to analysts ...

Shares in biopharmaceutical company Viking Therapeutics (NASDAQ: VKTX) were up by 6.3% at 12:30 a.m. ET today. The move ...

Earlier this week, the pharma giant publicly accused Hims & Hers of “deceptive” marketing that is putting patient safety at risk.

The UK's health regulator is investigating Ozempic and Mounjaro after linking the drugs to hundreds of severe illnesses and ...

Empagliflozin has kidney protective effects and reduces heart failure outcomes across baseline kidney function among patients ...

Mounjaro is one of the bestselling weight loss drugs. See what your options are if you want to invest in Mounjaro stock.

Eli Lilly faces market headwinds, slowing growth, and rising competition. Discover why now might be the time for LLY ...

For high-risk patients with type 2 diabetes, oral semaglutide reduced risk for major cardiovascular and ischemic limb-related ...

Jefferies analysts called the proxy filing, which is a standard disclosure after a merger agreement, “much more intriguing ...